Deutsche Bank To Elect Alex Wynaendts As Chairman; Names Olivier Vigneron Group Chief Risk Officer

German banking major Deutsche Bank AG's (DB) CEO Christian Sewing said the Supervisory Board intend to elect Alex Wynaendts as Chairman.

The Board plans to propose to shareholders at the Annual General Meeting on May 19, 2022 that Wynaendts be elected to the Supervisory Board.

The company noted that Paul Achleitner, Chairman of the Supervisory Board, had made an early decision not to run for the Supervisory Board again after 10 years in office.

Separately, the company said Olivier Vigneron has been designated as Deutsche Bank's Group Chief Risk Officer, effective June 1, 2022.

Subject to regulatory approvals, he will succeed Stuart Lewis, who in March announced his decision to retire after the Annual General Meeting 2022 after 25 years' service.

Vigneron will join Deutsche Bank as a Senior Group Director on March 1, 2022. He is joining Deutsche Bank from Natixis, where he served as Chief Risk Officer since 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT